News
Japan’s Ministry of Health, Labour and Welfare (MHLW) has accepted UK pharma major GSK’s regulatory application to expand the ...
Japanese regulators have accepted GSK's application to expand the use of its RSV vaccine, Arexvy, to the entire adult ...
GSK has applied to the European Medicines Agency to expand use of its respiratory syncytial virus (RSV) vaccine to adults ...
(Alliance News) - GSK PLC on Friday announced that Japan has accepted a regulatory application to expand the use of its respiratory syncytial virus [RSV] vaccine Arexvy.
GSK (LSE:GSK) announced that the European Medicines Agency accepted its regulatory application to expand the use of its RSV ...
Housebuilder Berkeley posted a 5% fall in annual earnings but said it was confident about the future against a backdrop of falling interest rates and government plans to ramp up supply using ...
GSK RSV vaccine Arexvy accepted for regulatory review by EMA to expand use in adults 18 years, older
London: GSK plc has announced that the European Medicines Agency (EMA) has accepted the company's regulatory application to ...
After nearly 25 years with Sanofi, Sanjay Gurunathan, M.D., has left for GSK, where he will lead vaccine and infectious ...
The Food and Drug Administration expanded the approval of Moderna’s RSV vaccine on Thursday, extending the license to include ...
GSK said on Friday the European Medicines Agency had accepted the drugmaker's application to expand the use of its ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results